- Home
- DAC vs SPRY Comparison
DAC vs SPRY Comparison
Compare DAC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAC
- SPRY
- Stock Information
- Founded
- DAC 1972
- SPRY 2015
- Country
- DAC Greece
- SPRY United States
- Employees
- DAC N/A
- SPRY 24
- Industry
- DAC Marine Transportation
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- DAC Consumer Discretionary
- SPRY Health Care
- Exchange
- DAC Nasdaq
- SPRY Nasdaq
- Market Cap
- DAC 1.6B
- SPRY 1.1B
- IPO Year
- DAC 2006
- SPRY N/A
- Fundamental
- Price
- DAC $79.84
- SPRY $11.41
- Analyst Decision
- DAC Strong Buy
- SPRY Strong Buy
- Analyst Count
- DAC 1
- SPRY 4
- Target Price
- DAC $105.00
- SPRY $24.00
- AVG Volume (30 Days)
- DAC 134.3K
- SPRY 1.1M
- Earning Date
- DAC 02-11-2025
- SPRY 11-13-2024
- Dividend Yield
- DAC 4.07%
- SPRY N/A
- EPS Growth
- DAC 0.27
- SPRY N/A
- EPS
- DAC 28.90
- SPRY N/A
- Revenue
- DAC $1,005,246,000.00
- SPRY $2,568,000.00
- Revenue This Year
- DAC $1.25
- SPRY $66,750.00
- Revenue Next Year
- DAC $5.60
- SPRY $508.63
- P/E Ratio
- DAC $2.75
- SPRY N/A
- Revenue Growth
- DAC 2.92
- SPRY 8460.00
- 52 Week Low
- DAC $69.33
- SPRY $5.19
- 52 Week High
- DAC $98.25
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- DAC 48.75
- SPRY 35.74
- Support Level
- DAC $75.52
- SPRY $10.80
- Resistance Level
- DAC $79.67
- SPRY $14.50
- Average True Range (ATR)
- DAC 1.82
- SPRY 0.77
- MACD
- DAC 0.01
- SPRY -0.12
- Stochastic Oscillator
- DAC 60.59
- SPRY 20.20
About DAC Danaos Corporation
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.